ClinVar Miner

Submissions for variant NM_000249.4(MLH1):c.1451del (p.Asp484fs)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV004018116 SCV004848305 likely pathogenic Lynch syndrome 2019-10-14 criteria provided, single submitter clinical testing The p.Asp484ValfsX7 variant in MLH1 has been previously reported in at least 1 individual with Lynch syndrome (Sjursen 2016) and was absent from large population studies. It is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 484 and leads to a premature termination codon 7 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozygous loss of function of the MLH1 gene is an established disease mechanism in individuals with Lynch syndrome. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant Lynch syndrome. ACMG/AMP Criteria applied: PVS1, PM2.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.